Long-term Oncologic Outcomes of Robotic-assisted Radical Prostatectomy by a Single Surgeon

Anticancer Res. 2017 Aug;37(8):4157-4164. doi: 10.21873/anticanres.11803.

Abstract

Aim: The aim of the study was to evaluate the long-term oncology outcomes of prostate cancer patients receiving robotic-assisted radical prostatectomy (RARP).

Patients and methods: We retrospectively evaluated 111 patients with clinically-localized prostate cancer receiving RARP with a mean follow-up of 103.43 months.

Results: The 5-year BCRFS and 8-year BCRFS among low-, intermediate-, and high-risk patients were 95.5% vs. 77.1% vs. 53.7% and 95.5% vs. 61.2% vs. 48.1% (p=0.000). The median time to BCR in these three groups was 122.5, 98.0, and 79.2 months. Regarding postoperative factors, positive lymph node (HR=3.748, 95% CI=1.407-9.984), pathology Gleason score (HR=1.507, 95%CI=1.010-2.248), and postoperative nadir PSA <0.003 ng/ml (HR=0.058, 95%CI=0.020-0.166) were independent risk factors for BCR.

Conclusion: D'Amico risk classification was effective at predicting biochemical recurrence in patients receiving RARP. Furthermore, postoperative risk factors such as metastatic lymph node, pathology Gleason score, and nadir PSA <0.003 ng/ml were independent predictors of biochemical recurrence.

Keywords: Biochemical recurrence; long term follow-up; prostate cancer; robotic prostatectomy.

MeSH terms

  • Aged
  • Disease-Free Survival
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Neoplasm Grading
  • Neoplasm Recurrence, Local / pathology
  • Neoplasm Recurrence, Local / surgery*
  • Neoplasm Staging
  • Prostatectomy / adverse effects*
  • Prostatic Neoplasms / pathology
  • Prostatic Neoplasms / surgery*
  • Risk Factors
  • Robotic Surgical Procedures / adverse effects*
  • Surgeons
  • Treatment Outcome